Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.

Autor: Chen, Qitong, Ouyang, Dengjie, Anwar, Munawar, Xie, Ning, Wang, Shouman, Fan, Peizhi, Qian, Liyuan, Chen, Gannong, Zhou, Enxiang, Guo, Lei, Gu, Xiaowen, Ding, Boni, Yang, Xiaohong, Liu, Liping, Deng, Chao, Xiao, Zhi, Li, Jing, Wang, Yunqi, Zeng, Shan, Hu, Jinhui
Předmět:
Zdroj: Frontiers in Oncology; 3/5/2021, Vol. 11, pN.PAG-N.PAG, 2p
Abstrakt: Breast cancer, metastases, HER2, pyrotinib, tumor mutation burden Keywords: breast cancer; HER2; pyrotinib; tumor mutation burden; metastases EN breast cancer HER2 pyrotinib tumor mutation burden metastases N.PAG N.PAG 2 03/10/21 20210305 NES 210305 In the original article, there was an error. [Extracted from the article]
Databáze: Complementary Index